Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
Summary
Trial Summary
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
Name: Site Public Contact
Email:
Phone: 310-423-8965
Email:
Phone: 310-423-8965
Name: David Oveisi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Richard L. Deming
Email:
Phone:
Email:
Phone:
Name: Richard L. Deming
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 515-241-3305
Email:
Phone: 515-241-3305
Name: Richard L. Deming
Email:
Phone:
Email:
Phone:
Name: Sarah A. Holstein
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 402-559-5600
Email:
Phone: 402-559-5600
Name: Sarah A. Holstein
Email:
Phone:
Email:
Phone:
Name: Sarah A. Holstein
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 212-639-7592
Email:
Phone: 212-639-7592
Name: Hamza Hashmi
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Alison K. Conlin
Email:
Phone:
Email:
Phone:
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 832-522-2873
Email:
Phone: 832-522-2873
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 281-242-2873
Email:
Phone: 281-242-2873
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Lisa X. Lee
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 916-734-3089
Email:
Phone: 916-734-3089
Name: Aaron Rosenberg
Email:
Phone:
Email:
Phone:
Name: Brion V. Randolph
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Mark A. Schroeder
Email:
Phone:
Email:
Phone:
Name: Site Public Contact
Email:
Phone: 864-241-6251
Email:
Phone: 864-241-6251
Name: Suzanne R. Fanning
Email:
Phone:
Email:
Phone:
Name: Brion V. Randolph
Email:
Phone:
Email:
Phone:
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Siddhartha Ganguly
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
Name: Peter J. Polewski
Email:
Phone:
Email:
Phone:
